September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Inhibition of Type II Iodothyronine Deiodinase Preserves Cones in Mouse
Models of Retinal Degeneration
Author Affiliations & Notes
  • Fan Yang
    Cell Biology, University of Oklahoma Health Sciences Center , Oklahoma City, Oklahoma, United States
  • Hongwei Ma
    Cell Biology, University of Oklahoma Health Sciences Center , Oklahoma City, Oklahoma, United States
  • Josh Belcher
    Cell Biology, University of Oklahoma Health Sciences Center , Oklahoma City, Oklahoma, United States
  • Michael Redmond
    Laboratory of Retinal Cell and Molecular Biology, National Eye Institute, Bethesda, Maryland, United States
  • Xi-Qin Ding
    Cell Biology, University of Oklahoma Health Sciences Center , Oklahoma City, Oklahoma, United States
  • Footnotes
    Commercial Relationships   Fan Yang, None; Hongwei Ma, None; Josh Belcher, None; Michael Redmond, None; Xi-Qin Ding, None
  • Footnotes
    Support  This work was supported by grants from the National Eye Institute (P30EY12190, R01EY019490, R21EY024583, and T32EY023202) and the Foundation Fighting Blindness.
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 181. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Fan Yang, Hongwei Ma, Josh Belcher, Michael Redmond, Xi-Qin Ding; Inhibition of Type II Iodothyronine Deiodinase Preserves Cones in Mouse
      Models of Retinal Degeneration. Invest. Ophthalmol. Vis. Sci. 2016;57(12):181.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Thyroid hormone (TH) signaling regulates cell proliferation, differentiation, and metabolism. In the retina, TH signaling plays a central role in cone opsin expression. Suppressing thyroid hormone (TH) signaling by anti-thyroid treatment reduces cone death in retinal degeneration mice. The intracellular TH signaling is regulated by the type II iodothyronine deiodinase (DIO2) which catalyzes the conversion of the prohormone thyroxine (T4) to the active hormone triiodothyronine (T3). This work investigates the effectiveness of inhibition of DIO2 in cone protection.

Methods : Inhibition of DIO2 was achieved by the use of the pharmacological inhibitor iopanoic acid (IOP). The effects of IOP were first tested in the photoreceptor-derived WERI-Rb1 cells. We pretreated cells with IOP for 16 hours, followed by treatment with T4 for 24 hours. At the end of the experiments, cells were harvested for analysis of mRNA expression of M-opsin by q-RT PCR. In the animal drug treatment experiments, postnatal day 7 (P7) Rpe65-/- or Rpe65-/-/Nrl-/- mice were intravitreally injected with IOP or vehicle. Mice were analyzed for cone death by terminal deoxynucleotidyltransferase dUTP nick end-labeling (TUNEL) at P15, and for cone density by immunofluorescence labeling of cone markers at P25. Expression of DIO2 in the mouse retina was examined by immunofluorescence labeling.

Results : We found that IOP inhibited T4-induced M-opsin expression in WERI cells in a concentration-dependent pattern, and treatment with IOP significantly improved cone survival in retinal degeneration mice. The number of TUNEL-positive cells in IOP-treated Rpe65-/-/Nrl-/- mice decreased by about 25%, compared with vehicle-treated controls. Cone density, evaluated by labeling of peanut agglutinin (PNA), cone arrestin (CAR), and cone opsin, increased significantly in IOP-treated Rpe65-/- mice, compared with vehicle-treated controls. The expression study showed that DIO2 immunoreactivity was detected in the inner segment area, and it co-localized with ATPase α1, which is consistent with its primary localization to the endoplasmic reticulum.

Conclusions : Our results show that pharmacological inhibition of DIO2 in the retina reduces cone death in retinal degeneration mice. The findings of this work provide insights into cone preservation and therapeutic interventions in retinal degeneration.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×